Enanta Pharmaceuticals (STU:9EP) ROCE %: -14.22% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9EP Enanta Pharmaceuticals Inc STU:9EP
58 GF Score
Price €11.50
GF Value €7.65
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Enanta Pharmaceuticals ROCE %?

Enanta Pharmaceuticals STU:9EP 58 ROCE % is -14.22% as of Mar. 2026. GuruFocus rates STU:9EP with a GF Score™ of 58/100 and a GF Value™ of €7.65 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Enanta Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was -14.22%.

Enanta Pharmaceuticals  (STU:9EP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Enanta Pharmaceuticals ROCE % Related Terms

Enanta Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Enanta Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enanta Pharmaceuticals ROCE % Chart

Enanta Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24.90 -35.71 -32.60 -29.09 -26.64

Enanta Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.34 -24.07 -26.41 -13.68 -14.22
STU:9EP
58GF Score
Enanta Pharmaceuticals Inc STU:9EP
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enanta Pharmaceuticals ROCE % Calculation

Enanta Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Sep. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=-64.64/( ( (339.363 - 51.839) + (239.184 - 41.369) )/ 2 )
=-64.64/( (287.524+197.815)/ 2 )
=-64.64/242.6695
=-26.64 %

Enanta Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-33.796/( ( (281.396 - 38.198) + (272.219 - 40.172) )/ 2 )
=-33.796/( ( 243.198 + 232.047 )/ 2 )
=-33.796/237.6225
=-14.22 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -14.22% mean?
Enanta Pharmaceuticals (STU:9EP) has a ROCE % of -14.22% as of Mar. 2026.
Is Enanta Pharmaceuticals' ROCE % too high?
Enanta Pharmaceuticals' current ROCE % is -14.22%. Overall, Enanta Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enanta Pharmaceuticals' ROCE % compare to PBYI and IPSC?
Enanta Pharmaceuticals' ROCE % of -14.22% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Enanta Pharmaceuticals's current ROCE % is -14.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enanta Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Enanta Pharmaceuticals (STU:9EP) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.65, compared to a current price of €11.50 — trading 50.3% above its estimated fair value. The current ROCE % is -14.22%. Enanta Pharmaceuticals' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Enanta Pharmaceuticals (STU:9EP), the current ROCE % is -14.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enanta Pharmaceuticals (STU:9EP) Overvalued in 2026?

Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued. The current stock price of €11.50 is trading 50.3% above its estimated GF Value™ of €7.65. GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:9EP:

  • ROCE %: -14.22%
  • GF Value™: €7.65 vs. price of €11.50 (50.3% above fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the STU:9EP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enanta Pharmaceuticals Business Description

Other Exchanges ENTA:USA9EP:Germany
Address 4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
58GF Score

Get the complete analysis for STU:9EP

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.50
Price
€7.65
GF Value